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Summary
Background Artemisinin combination therapies (ACTs) are used worldwide as ﬁ rst-line treatment against conﬁ rmed 
or suspected Plasmodium falciparum malaria. Despite the success of ACTs at reducing the global burden of malaria, 
emerging resistance to artemisinin threatens these gains. Countering onset of resistance might need deliberate 
tactics aimed at slowing the reduction in ACT eﬀ ectiveness. We assessed optimum use of ACTs at the population 
level, speciﬁ cally focusing on a strategy of multiple ﬁ rst-line therapies (MFT), and comparing it with strategies of 
cycling or sequential use of single ﬁ rst-line ACTs.
Methods With an individual-based microsimulation of regional malaria transmission, we looked at how to apply a 
therapy as widely as possible without accelerating reduction of eﬃ  cacy by drug resistance. We compared simultaneous 
distribution of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine (ie, MFT) 
against strategies in which these ACTs would be cycled or used sequentially, either on a ﬁ xed schedule or when 
population-level eﬃ  cacy reaches the WHO threshold of 10% treatment failure. The main assessment criterion was 
total number of treatment failures per 100 people per year. Additionally, we analysed the beneﬁ ts of including a single 
non-ACT therapy in an MFT strategy, and did sensitivity analyses in which we varied transmission setting, treatment 
coverage, partner-drug half-life, ﬁ tness cost of drug resistance, and the relation between drug concentration and 
resistance evolution.
Findings Use of MFT was predicted to reduce the long-term number of treatment failures compared with strategies in 
which a single ﬁ rst-line ACT is recommended. This result was robust to various epidemiological, pharmacological, 
and evolutionary features of malaria transmission. Inclusion of a single non-ACT therapy in an MFT strategy would 
have substantial beneﬁ ts in reduction of pressure on artemisinin resistance evolution, delaying its emergence and 
slowing its spread.
Interpretation Adjusting national antimalarial treatment guidelines to encourage simultaneous use of MFT is likely to 
extend the useful therapeutic life of available antimalarial drugs, resulting in long-term beneﬁ cial outcomes for patients.
Funding Wellcome Trust, UK Medical Research Council, Li Ka Shing Foundation.
Copyright © Nguyen et al. Open Access article distributed under the terms of CC BY.
Introduction
During the next decade, substantial public health eﬀ ort 
and ﬁ nancial resources will be expended to eliminate 
malaria in as many parts of the world as possible.1 In 
this endeavour, several antimalarial strategies will be 
used, including antimalarial treatment for clinically 
acute cases, antimalarial chemoprophylaxis in at-risk 
populations, insecticide-treated nets, household 
insecticide use, improved diagnostics, and expansion of 
health service delivery.2 For some of these interventions, 
long-term diminishing returns as drug or insecticide 
resistance emerges and as mosquitoes adapt their 
behaviour to insecticide-treated nets and insecticide 
application are of concern. Eﬀ orts to maximise eﬀ ects 
of elimination campaigns and to minimise the chances 
of an emergent drug or insecticide resistance 
phenomenon occurring during this period are 
important.3 Such an event would seriously undermine 
the ambition and progress of malaria elimination 
programmes.
Since 2005, WHO has strongly endorsed ﬁ rst-line use of 
artemisinin-based combination therapies (ACTs) for 
uncomplicated Plasmodium falciparum malaria because of 
their safety and rapid action against asexual blood stages, 
including some transmission stages.4,5 Additionally, WHO 
discouraged artemisinin mono therapy to reduce 
recrudescence rates and to decrease the probability of de-
novo artemisinin resistance emerging in individual 
patients. The partner drug in a coformulated ACT is 
always eliminated more slowly than the rapidly eliminated 
artemisinin derivatives, providing protection during the 
course of treatment against de-novo emergence of an 
artemisinin-resistant genotype. For artemisinin resistance 
to emerge, a parasite must be capable of surviving 
exposure to artemisinin and the partner drug—a highly 
improbable event unless the infecting parasite population 
already carries resistance genes to the partner drug.
Despite these precautions aimed at preserving eﬃ  cacy 
of artemisinin-based therapies, artemisinin resistance still 
warrants serious concern. A partly resistant, slow-clearing 
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P falciparum phenotype emerged in Cambodia in the 
1980s or 1990s.6,7 This phenotype was later seen on the 
border between Thailand and Myanmar8 and in southern 
Vietnam near the Cambodian border,9,10 and is now 
established in much of mainland southeast Asia.10,11 Slow 
parasite clearance is strongly associated with a group of 
polymorphisms in the P falciparum kelch propeller 
domain.6,10 When devising strategies to contain or 
extinguish this resistant genotype, the potential for 
stronger resistance and emergence of a fully artemisinin-
resistant genotype in the next decade should also be 
considered.
Artemisinin pressure on parasites is likely to increase 
during the next decade for the following reasons: ACTs 
will remain the most commonly used antimalarial 
therapies; existing partner-drug resistance is likely to 
spread to areas where the corresponding ACTs are used; 
and artemisinin monotherapies are still likely to be used 
to some extent in contravention of strong WHO 
and national-level health policy recommendations. 
Additionally, in individual patients, underdosing with 
artemisinin-based drugs might be a concern because 
subtherapeutic doses create an environment favourable to 
ﬁ xation of drug-resistant genotypes.12 Underdosing might 
occur as a result of substandard drugs,13 insuﬃ  cient 
absorption, poor adherence practices, or prescription of 
subtherapeutic doses, especially in hyperparasitaemic 
patients (who need higher doses than patients with lower 
parasite densities) and young children or pregnant women 
(who have low drug exposures).12,14 For these reasons, 
additional measures should be taken to ensure that the 
evolutionary selection pressure for artemisinin-resistant 
genotypes is as low as possible for as long as possible.
A key biological principle underpinning potential 
strategies for slowing down evolution and spread of a 
novel mutant is that evolution occurs slowly in 
heterogeneous or variable environments.15 Combination 
therapy takes advantage of this principle by introducing 
drug heterogeneity into a pathogen’s environment and 
forcing the pathogen population to adapt to several new 
environmental features simultaneously. This principle 
can be applied at the population level, if a parasite 
encounters diﬀ erent drugs in diﬀ erent individuals. The 
two frequently explored approaches to achieve this eﬀ ect 
are drug cycling—in which a single therapy is used 
population-wide for a speciﬁ c amount of time before 
being replaced with a diﬀ erent therapy—and 
simultaneous distribution of several therapies in a 
population. Both strategies have been assessed with 
mathematical models for bacteria16–18 and malaria,19–22 and 
simultaneous distribution is generally more eﬀ ective 
than drug cycling at delaying resistance evolution and 
keeping prevalence low for a longer period. One of the 
reasons is that, with a strategy of simultaneous 
distribution of diﬀ erent drugs, the parasite’s 
environment is more variable than with a cycling 
strategy.18,19 In this scenario, even if a de-novo resistant 
parasite were to emerge in a single host, it would have 
diﬃ  culty establishing itself in the population because 
the parasite’s next host would have at least a 50% chance 
of not being treated with the same drug. This eﬀ ect 
would be as strong in a cycling strategy only if the drugs 
were cycled in and out rapidly, on the order of the 
generation time of the infection.
We assessed optimum distribution of ACTs at the 
population level, speciﬁ cally focusing on a strategy of 
multiple ﬁ rst-line therapies (MFT)19—in which therapies 
are simultaneously recommended as ﬁ rst-line and are 
prescribed to individual patients according to a random 
factor (eg, day of week or true randomisation)—and 
comparing it with strategies of cycling or sequential use 
of single ﬁ rst-line ACTs. We developed and validated an 
individual-based microsimulation, which is an advance 
over previous eﬀ orts to address this question because it 
accounts for key features of malaria epidemiology that 
aﬀ ect patterns of resistance evolution: age-speciﬁ c 
immune acquisition, biting rate heterogeneity, drug 
pharmacokinetics and pharmacodynamics, asexual 
parasite density, multiplicity of infection, and 
recombination.
Panel: Research in context
Evidence before this study
We searched PubMed combining the term “malaria OR 
plasmodium OR falciparum” with “treatment strategy” 
(22 results), “resistance management” (77 results), “multiple 
ﬁ rst” (seven results), “multiple drugs” (22 results), “two drugs” 
(92 results), and “drug distribution” (25 results), which yielded 
three publications in which mathematical models were used to 
compare diﬀ erent methods of distributing several available 
antimalarial therapies.
Added value of this study
The model presented here is an advance over these studies 
because it includes individual-level host detail, age-speciﬁ c 
eﬀ ects, explicit tracking of within-host parasite density, and 
drug-speciﬁ c pharmacodynamics. Additionally, we validated 
the present model’s behaviour against a range of ﬁ eld and 
clinical datasets to ensure that the model replicates well known 
clinical and epidemiological patterns of Plasmodium falciparum 
malaria.
Implications of all the available evidence
At national or regional levels, simultaneous use of multiple 
ﬁ rst-line artemisinin combination therapies should be 
recommended, because this approach will delay emergence 
and evolution of artemisinin-resistant parasites and 
partner-drug-resistant parasites. 
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Methods
Study design 
We developed an individual-based stochastic micro-
simulation of P falciparum transmission (appendix). 
The model tracks 1 million individuals for 20 years, 
and assesses which population-level approaches to 
distribution of ACTs most eﬀ ectively reduce the 
cumulative number of treatment failures over 20 years 
and minimise the risk of emergence of a novel 
artemisinin-resistant genotype.
Validation
For some model parameters, such as duration of 
infection or parasite density levels, we obtained direct 
measurements from ﬁ eld or clinical data and input them 
into the model (appendix). When direct measurements 
were not available—eg, for age-speciﬁ c rates of immune 
acquisition—we validated the model by comparing 
model outputs with the corresponding ﬁ eld observations 
(appendix). When a behaviour could vary greatly—eg, the 
relation between drug concentration and probability that 
a drug-resistant mutant will emerge—we assessed 
several possibilities in a sensitivity analysis.
Strategy comparison and assessment criteria
We assumed that three ACTs with diﬀ erent partner drugs 
were available for treatment. We set half-lives used for the 
three partner drugs to 4·5 days for lumefantrine, 9 days 
for amodiaquine, and 28 days for piperaquine.23–26 We 
compared three population-level treatment strategies in 
the simulations. The ﬁ rst strategy is use of MFT, in which 
a third of individuals are treated with artemether–
lumefantrine, a third with artesunate–amodiaquine, and 
a third with dihydroartemisinin–piperaquine. The second 
strategy is a cycling strategy, in which a single ACT is 
used in the population at any one time and the ACTs are 
rotated on a 5-year schedule; shorter half-life ACTs are 
rotated in ﬁ rst, so the sequence is artemether–
lumefantrine, artesunate–amodiaquine, then dihydro-
artemisinin–piperaquine. The third strategy mimics the 
standard approach of cycling or sequentially using ﬁ rst-
line therapies until they begin to fail. This strategy is 
called sequential deployment, and therapies are replaced 
when the treatment failure rate (with a 60-day moving 
average) reaches the WHO-deﬁ ned4 criterion of 10%; a 
1-year delay is built in to this strategy, because switching 
ﬁ rst-line drugs at the national level usually takes longer 
than 1 year.27
We used four assessment criteria. The total number of 
treatment failures per 100 people per year, discounted at 
3% annually, is the main assessment criterion for 
comparing strategies; non-treatments are counted as 
treatment failures in this calculation. The useful 
therapeutic life of a strategy is deﬁ ned as the amount of 
time a strategy can be used before we see 10% treatment 
failure population-wide; for comparison, in the cycling 
and sequential deployment strategies, we count the total 
time in the simulation that the treatment failure rate is 
below 10% and deﬁ ne this as the useful therapeutic life. 
We deﬁ ne time until resistance emergence (T0·01) as the 
time at which the genotype frequency of all resistant 
alleles (appendix) reaches 1%, and we used this as an 
approximate threshold of when resistant genotypes 
progress from rare to nearly established. Finally, we 
monitored artemisinin monotherapy use; we deﬁ ne de-
facto artemisinin monotherapy use as ACT treatment of 
an infection with partner-drug resistance. We report the 
total number of individual cases of artemisinin 
See Online for appendix
Figure 1: Expected patterns of drug-resistance evolution and corresponding 
malaria prevalence for three treatment regimens
We ran 100 stochastic simulations in a population of 1 million individuals, in a 
low-transmission setting (entomological inoculation rate=1·3) with 60% 
treatment coverage and an assumed cost of resistance of 0·5% for resistant 
genotypes. The mutation rate is assumed to be highest for intermediate drug 
concentrations. The red line shows the median prevalence across 
100 simulations, and the red regions show the IQR and 90% range. The median 
number of treatment failures (NTF) with IQRs are shown in each panel 
(p<0·0001 when comparing multiple ﬁ rst-line therapies to the other two 
strategies). The dashed line shows 5% prevalence. For the cycling and sequential 
strategies, after emergence of a novel drug-resistant type, an epidemiological 
rebound sometimes causes prevalence to reach higher-than-expected levels 
(here, >6%) for short periods.
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monotherapy use in a 20-year simulation, which 
measures how exposed (ie, not protected by a partner 
drug) artemisinin drugs are to resistance evolution.
Statistical analysis
When comparing two strategies, we tested statistically 
for rank diﬀ erences in the outcome measures (Mann-
Whitney test) and diﬀ erences between the medians and 
IQR (Mood’s test). To summarise, we present the 
maximum of these four p values, unless stated otherwise.
We did sensitivity analyses to identify eﬀ ects of 
diﬀ erences in transmission setting, treatment coverage, 
partner-drug half-life, ﬁ tness cost of drug resistance, and 
the relation between drug concentration and resistance 
evolution (appendix).
Role of the funding source
The funders of the study had no role in model design, 
analysis, interpretation, or writing of the report. The 
corresponding author had full access to all model code, 
validation results, simulation results, and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Use of MFT had consistently better population-level 
outcomes than cycling and sequential deployment 
strategies, and the superior performance of MFT was 
robust in various transmission, clinical, and evolutionary 
settings. As noted in previous modelling studies,18,19 an 
MFT strategy creates a more variable environment than 
drug cycling, which results in delayed resistance 
emergence and slower drug-resistance evolution. This 
eﬀ ect is seen even when allowing for free recombination 
among resistance loci, which was previously raised as a 
potential concern when assessing the beneﬁ ts and 
drawbacks of MFT strategies.28 Figure 1 shows typical 
evolutionary and epidemiological trajectories for malaria 
in the three treatment strategies we assessed.
A strategy comparison in a low-transmission setting 
corresponding to an entomological inoculation rate of 
1·3 infectious bites per person per year shows signiﬁ cant 
variation, owing to the stochastic nature of the model, 
in the number of treatment failures (ﬁ gure 2) and the 
time until resistance emergence (T0·01; ﬁ gure 3). In some 
high-coverage settings, treatment drives the parasite 
population to extinction before drug resistance emerges. 
When resistance evolves (0·5≤f≤0·7), MFT strategies 
have median numbers of treatment failures 16–41% 
lower (p=0·003; Mood’s test) than either the sequential 
strategy or the cycling strategy; this diﬀ erence is larger 
for higher costs of resistance. Additionally, elimination 
was seen more often with MFT strategies since these 
strategies preserve full drug eﬃ  cacy for longer than do 
the cycling or sequential strategies. Figure 3 shows that 
low numbers of treatment failures are closely associated 
with long times to resistance emergence. MFT strategies 
have a higher mean and more variation in their 
associated time-to-emergence (an expected outcome for 
a waiting process) than do cycling strategies, resulting 
in a higher proportion of simulations in which 
resistance emerges very late or not at all during the 
20-year model simulation.
Figure 2: Median number of treatment failures (NTFs) for diﬀ erent strategies, diﬀ erent costs of resistance (CR), and diﬀ erent treatment coverages (f)
Each row shows the NTF results of 100 model simulations with bars spanning the IQR. NTF values are lower for multiple ﬁ rst-line therapies than for cycling or sequential strategies; all p<0·0001, 
except for the comparisons *, for which p=0·01. For f≥0·7, the NTF distributions have a bimodal shape, with NTF<0·5 corresponding to simulations that achieved extinction or near-extinction; the 
numbers on the left-hand side of each boxplot show the counts of these extinctions or near-extinctions, and the IQRs are plotted only for simulations that did not result in extinction. Simulations 
assume that three artemisinin combination therapies with 95% eﬃ  cacy are used in a low-transmission setting with an entomological inoculation rate of 1·3. Drug resistance mutations have their 
highest probability of ﬁ xation at intermediate drug concentrations.
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Because these model simulations rely partly on 
prediction of rare events (emergence of artemisinin 
resistance), we ran a separate set of simulations to quantify 
risk of artemisinin resistance using the artemisinin 
monotherapy use criterion: the total number of cases 
during the 20-year simulation in which a partner-drug-
resistant infection was treated with an ACT (ﬁ gure 4). 
Excluding one comparison set in this ﬁ gure, the median 
artemisinin monotherapy use values for MFT strategies 
were 28–78% lower (p<0·0001; Mood’s test) than for 
cycling or sequential use, suggesting that MFT strategies 
might have a much lower risk of selecting for de-novo 
artemisinin resistance. MFT strategies delay and decelerate 
partner-drug resistance evolution, thus prolonging the 
time that artemisinin-based drugs are used as combination 
therapies with both components eﬀ ective.
We did a comprehensive set of simulations to vary 
transmission setting, biting rate heterogeneity, treatment 
coverage, relation between drug concentration and 
mutation, drug half-life, and ﬁ tness cost of resistance. 
Excluding extinctions, MFT strategies were associated 
with the lowest number of treatment failures of any 
treatment strategy in 4434 (86·2%) of 5146 simulations; 
extinctions were most common with MFT. The median 
reduction in treatment failures achieved by MFT was 
10·6% (IQR 2·9–20·0; p<0·0001) compared with a 5-year 
cycling strategy, and 9·6% (3·0–18·6; p<0·0001) 
compared with sequential deployment (appendix).
In addition to deploying MFT, we considered other 
possibilities that would enable us to preserve the 
eﬃ  cacy of artemisinin-based drugs for as long as 
possible. From the analyses presented here and basic 
evolutionary theory, alleviating parasites from 
artemisinin drug pressure should slow down evolution 
of artemisinin resistance. Use of a non-ACT alongside 
two artemisinin-based therapies in an MFT strategy 
Figure 3: Number of treatment failures (NTF) plotted against the time taken to reach an average of 1% resistance frequency in the population 
Variance in time-to-emergence is greater for MFT strategies than for cycling or sequential strategies, resulting in a subset of simulations with long emergence times.
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should have this eﬀ ect. Clearly, the major consideration 
for such a strategy is whether the non-ACT component 
is as eﬀ ective and safe as an ACT. If this individual-level 
acceptability criterion is met, an MFT strategy with a 
single non-ACT therapy29 could substantially extend the 
lifespan of artemisinins. Figure 5 shows the lower 
number of treatment failures and longer useful 
therapeutic life that would be associated with this 
strategy, the lower number of treatment failures being a 
direct result of a longer time to emergence of 
artemisinin resistance. In these simulations, treatment 
coverage was 60%; thus, even in the worst-case scenario 
of 75% eﬃ  cacy for a non-ACT therapy, only 4% of 
symptomatic malaria cases in the model had treatment 
failure as a result of not receiving an ACT. In the six 
scenarios in ﬁ gure 5, the median time to emergence for 
a strategy with a non-ACT was 43–72% longer (p=0·001; 
Mood’s test) than in a strategy with three ACTs. 
Additionally, with a mix of two ACTs and one non-ACT, 
a third ACT would be preserved in case one of the 
partner drugs began to fail early.
We investigated the possibility of targeting diﬀ erent 
age groups with diﬀ erent ACTs and changing usage 
frequencies for ACTs according to partner-drug half-life. 
We identiﬁ ed no simple method to optimise either of 
these strategies. A speciﬁ c challenge with an age-based 
treatment strategy is the changing age proﬁ le of 
symptomatic infections as transmission intensity 
decreases over time. Results of previous studies19,30,31 have 
described selection pressure for drug resistance 
increasing with lower transmission. However, our age-
structured model shows that this eﬀ ect has a strong 
interaction with age, with younger age groups exerting 
less selection pressure, and older age groups exerting 
more selection pressure, as transmission decreases 
(appendix). Adjustment of the distribution strategy 
according to half-life did not seem to have a large eﬀ ect 
on long-term treatment outcomes (appendix).
Discussion
Our analysis suggests that use of MFT strategies should 
result in improved population-level treatment outcomes, 
delayed resistance emergence, and slowed resistance 
evolution, as seen in previous, more general analyses.18–20,22 
Additionally, the major prevailing concern about MFT 
strategies—that they would enable recombination to 
generate multidrug-resistant types earlier than other 
strategies—proved not to be true in any of our 
simulations. The P falciparum transmission model we 
developed and validated for this study provides outcomes 
in accordance with expectations based on evolutionary 
theory: that challenging the parasite with an environment 
presenting several simultaneous lethal challenges 
signiﬁ cantly increases the time the parasite needs to 
defeat all of them.
Since population-level treatment strategies such as the 
ones assessed here will never be testable in the ﬁ eld, 
model-based recommendations might be the only 
evidence available to plan optimum distribution of 
antimalarial therapies. If the median predicted beneﬁ ts 
Figure 4: Comparisons of artemisinin monotherapy use for multiple ﬁ rst-line therapies (MFT), 5-year cycling, and sequential deployment
Artemisinin monotherapy use values are shown for diﬀ erent costs of resistance (cR), and diﬀ erent treatment coverages (f). Each row shows the artemisinin monotherapy results of 100 model 
simulations, with bars spanning the IQR. Artemisinin monotherapy use values are lower for MFT (all p=0·001) except for the comparisons corresponding to *. Simulations assume that three 
artemisinin combination therapies with 95% eﬃ  cacy are used in a low-transmission setting (entomological inoculation rate=1·3). Partner-drug resistance mutations have their highest probability of 
ﬁ xation at intermediate drug concentrations. Artemisinin monotherapy use decreases with treatment coverage because prevalence is lower when more individuals are treated.
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are a 16–41% reduction in treatment failures during a 
20-year period and a more than 40% increase in the 
useful therapeutic life of ACTs, model-based 
recommendations could be considered suﬃ  cient 
evidence for management of distribution and usage 
patterns of antimalarial drugs. As elimination campaigns 
move forward, MFT strategies might enable elimination 
eﬀ orts to succeed before a fully artemisinin-resistant 
genotype emerges.
The key principle in the strategy comparisons 
presented here is conservation of drug eﬃ  cacy.32 As 
drugs are used more sparingly, drug eﬃ  cacy is prolonged, 
and an MFT strategy enables individual drugs to be used 
sparingly without reducing the total number of patients 
intended to treat. The scenario presented in ﬁ gure 5 
speciﬁ cally considers the conservation of artemisinin 
eﬃ  cacy, and the potential for extending the useful 
therapeutic life of artemisinin drugs by pairing them 
with other highly eﬃ  cacious drugs in an MFT strategy. 
This conservation approach is logical from an 
evolutionary perspective, but ethical implications will 
need to be assessed carefully since some patients could 
be treated with a therapy with non-optimum measured 
eﬃ  cacy. To improve the chances that such a strategy 
meets the highest medical and ethical acceptability 
criteria, the risks for patients treated with a non-ACT 
would need to be mitigated, possibly through frequent 
follow-up and availability of second-line treatments.
As in all past analyses of the dynamics of drug-resistant 
parasites, measuring ﬁ tness costs33–38 of drug-resistant 
genotypes is crucial for prediction of the spread of 
resistance. For artemisinin resistance, the dynamic 
picture (2002–13) of the spread of kelch13 resistance-
associated alleles in Cambodia is the best starting point 
to investigate ﬁ tness costs. However, the ﬁ tness cost of 
any future hypothetical resistant genotype is impossible 
to predict. To be conservative, ﬁ tness costs in our analyses 
were varied between 0·1% and 1·0%, because scenarios 
with much higher ﬁ tness costs would result in a bigger 
advantage of MFT compared with cycling or sequential 
strategies.
In-depth critiques of model structure and validations 
are necessary when interpreting results from 
mathematical models. The model presented here does 
not take into account ﬁ ne-scale spatial structure, mosquito 
dynamics, gametocyte dynamics, genotype-speciﬁ c drug 
Figure 5: Comparison with a non-artemisinin combination therapy (ACT) drug included in a multiple ﬁ rst-line therapies (MFT) strategy
Comparisons between MFT strategies with three ACT components and MFT strategies in which one of the components in the treatment strategy is not an 
artemisinin-based therapy. Results of 100 simulations for each strategy are summarised as normal distributions for the number of treatment failures (NTF; shown in 
green out to ±2σ), and as gamma distributions for the time until frequency of artemisinin resistance reaches 1% (central 90% of distribution shown in green). 
Distributions of NTF and the time until 1% artemisinin resistance for three ACTs are signiﬁ cantly diﬀ erent (p=0·01) from the comparator distributions in which one 
non-ACT is used, except for the comparison labelled *, for which there was no diﬀ erence. The upper panels use a mutation model in which mutation rate is 
proportional to drug concentration. The lower panels show simulation results when the mutation rate increases at intermediate concentrations. Simulations assume 
that three ACTs with 95% eﬃ  cacy are used in a low-transmission setting (entomological inoculation rate=1·3). In the simulations with two ACTs, the shorter half-life 
ACTs were used (minimising selection pressure), and the non-ACT therapy is assumed to be a combination therapy with components that have 7-day and 10-day 
half-lives. Treatment coverage is f=0·6.
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eﬃ  cacies, or seasonal or climate eﬀ ects, but all these 
features should clearly be considered when planning 
treatment campaigns and elimination strategies. 
Continual development and validation of models by 
adding in realistic features that are known to have 
important eﬀ ects on malaria transmission and evolution 
are crucial so that every iteration of development brings 
the model closer to resembling the real-world 
epidemiology of malaria. Comparison of these results 
with those of other models (appendix) is crucial to test 
robustness. Analyses in many types of transmission 
settings need to be done to ensure that speciﬁ c policy 
recommendations are optimum. Our results suggest that 
MFT’s relative beneﬁ ts are smaller in higher transmission 
settings (appendix), but absolute beneﬁ ts do not show 
this pattern consistently.
Potential caveats about the beneﬁ ts of MFT strategies 
need to be addressed and evaluated. First, strategy 
comparisons will probably be sensitive to the parity of 
available therapies. In a scenario in which one ACT has 
much higher eﬃ  cacy than the other two, use of the high-
eﬃ  cacy therapy ﬁ rst might be prudent since this strategy 
would lower the parasite population size more quickly 
(across all hosts) than use of a lower eﬃ  cacy therapy, and 
would lower the probability of random mutation 
generating a drug-resistant genotype. Recommended 
and available ACTs have similar eﬃ  cacies,39 but this is 
location-dependent.40 Scenarios in which, for example, 
two treatments with 90% and 98% eﬃ  cacy have diﬀ erent 
predicted eﬀ ects on a desired epidemiological outcome 
such as elimination will need to be assessed on a case by 
case basis. Second, in choosing the optimum strategy we 
need to consider the multitude of resistance eﬀ ects 
caused by individual loci, an important example being 
position 76 in the chloroquine resistance transporter 
gene (pfcrt), in which the wild-type allele (K) confers 
lumefantrine resistance and the mutant allele (T) confers 
amodiaquine resistance.41,42 Cycling strategies usually 
have worse evolutionary outcomes than do other 
strategies because they drive evolution of individual 
resistance types more quickly, but in the case of K76T, 
amodiaquine resistance driving lumefantrine sensitivity 
might mitigate this problem. These eﬀ ects might be 
present for other loci.43,44
Implementation, compliance, and operations will be 
the next important areas of focus if MFT strategies are 
accepted as the best strategy for distribution and 
prescription of antimalarial drugs. Operationally, MFT 
would have several advantages because it removes the 
need for large system-wide changes in drug policy and 
avoids problems of obsolete drug stocks. Whether 
randomly assigning therapies should be done by 
location, day of week, a true randomisation scheme, or 
another method is unknown. Variation in drug purchase 
patterns from private and public sectors45,46 will 
necessitate diﬀ erent implementations, and compliance 
monitoring will be challenging in contexts with high 
levels of private sector drug purchases. Nevertheless, 
some countries have successfully managed roll-out of 
multiple ACTs,47–50 showing the feasibility of locally 
determined drug distribution and ﬂ exible treatment 
guidelines on the basis of changing epidemiology. A 
commitment to assessing the eﬀ ectiveness of new 
population-level malaria treatment programmes and a 
willingness to adapt approaches will be crucial to 
maximise the beneﬁ ts of MFT to global malaria policy.
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